Clinical trials: sponsored by M.D. Anderson Cancer Center
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Solid Tumor, Adult
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045.
- Trial name
- NCT06056323
- Testing
- HB0045 Drug Product
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Cancer, Predictive Cancer Model
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
- Conditions
- Cancer, Predictive Cancer Model, Effects of Chemotherapy
- Trial name
- NCT05338073
- Testing
- Known 3Dx Test
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Known Medicine, Inc.
Advanced Solid Tumors
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.
- Trial name
- NCT04659096
- Testing
- ION537
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypoxemia
SuperNO2VA Et Versus Oxygen Face Mask During Deep Sedation
The primary objective of the study is to prospectively and randomly compare the incidence, duration, and severity of oxygen desaturation between a nasal mask with nasal positive airway pressure (PAP) versus oxygen therapy with a…
- Trial name
- iOXYGENATE (NCT05175573)
- Testing
- SuperNO2VA Et Nasal Positive Pressure Mask, Supplemental Oxygen Face Mask
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Vyaire Medical
Breast Carcinoma
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
This study investigates if a new type of test called Droplet-BC screening test can classify breast cancer patients from non-cancer volunteers by circulating small-noncoding RNA in the blood with a statistical validity.
- Trial name
- NCT04671498
- Testing
- Biospecimen Collection, Droplet-BC Test, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Preferred Medicine, Inc
Malignant Abdominal Neoplasm, Malignant Head and Neck Neoplasm
Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery
This clinical trial studies the effect of behavioral health support including tele-health in helping surgical patients taper off of prescription opioid pain medications.
- Conditions
- Malignant Abdominal Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm
- Trial name
- NCT04963972
- Testing
- Behavioral Intervention, Best Practice, Questionnaire Administration
- Where
- United States
- Volunteers
- 272 people
- Sponsor
- Lucid Lane, Inc
Pediatric Cancer, Surgery
A Pilot Randomized Controlled Trial for Feasibility of Administering an AR Game to Postoperative Pediatric Cancer Patients
This is a pilot study to evaluate the feasibility of SpellBound's AR (augmented reality)-enabled scavenger hunt use among 20 pediatric cancer patients undergoing surgery.
- Trial name
- GAMING (NCT04674150)
- Testing
- ARISE with AR, ARISE without AR
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- ALTality, Inc.
Disorders of Breast, Breast Lesions
Magseed Magnetic Marker Localization
The purpose of this post-marketing study is to provide prospective evidence that the Magseed and Sentimag® is effective for lesion localization in patients undergoing surgical excision of a breast lesion and to summarize measures…
- Trial name
- NCT03020888
- Testing
- Magseed and Sentimag
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Endomagnetics Inc
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Leukemia, Lymphocytic, Chronic, B-Cell
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD)…
- Trial name
- NCT03265717
- Testing
- INVAC-1
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Invectys
Castrate Resistant Prostate Cancer (CRPC)
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1)…
- Trial name
- NCT00868595
- Testing
- BPX-101, AP1903
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bellicum Pharmaceuticals
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
A Multi-Center Trial of the ProLung Test™
The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer.
- Trial name
- NCT01566682
- Where
- 15 sites in United States
- Volunteers
- 420 people
- Sponsor
- Fresh Medical Laboratories
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
- Trial name
- NCT01211457
- Testing
- sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Hypoxemia, Acute Respiratory Failure
SuperNO2VA™ and General Anesthesia Postoperative Care
The purpose of the study is to randomly and prospectively evaluate the differences in outcomes between the control group (closed full facemask immediate post-extubation with standard oxygenating device used post-operatively in…
- Trial name
- NCT03969615
- Testing
- SuperNO2VA nasal positive airway pressure devic, Supplemental oxygen
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vyaire Medical
Cancer
Study of Oral PQR309 in Patients With Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
- Trial name
- NCT02483858
- Testing
- PQR 309
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- PIQUR Therapeutics AG
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Myelodysplastic Syndrome
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
This protocol is a follow-up for patients receiving continuation of OPN-305 monotherapy treatment or combination treatment with azacitidine after completion of the dose confirming, dose expansion and HMA naïve parts of the main…
- Trial name
- NCT03337451
- Testing
- OPN-305
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Opsona Therapeutics Ltd.
Myelodysplastic Syndrome
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
The dose-confirming part of this study, comprising at least 10 patients is designed as a single center, prospective, single arm, open label in patients who have failed or are unresponsive to Azacitidine (AZA) or Decitabine (they…
- Trial name
- NCT02363491
- Testing
- OPN-305
- Where
- 4 sites in United States
- Volunteers
- 96 people
- Sponsor
- Opsona Therapeutics Ltd.
Breast Cancer
A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer
This is a multicenter, blinded prospective study of 2,000 women undergoing mammography for breast -related symptoms or signs. Breath tests will be performed in order to demonstrate that the outcome of mammography results combined…
- Trial name
- NCT02888366
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Menssana Research, Inc.